SCHEDULE: Octagon Capital Discloses 7.8% Stake in Unicycive

Octagon Capital Advisors LP and affiliated funds, along with Ting Jia, have disclosed a combined 7.8% beneficial ownership stake in Unicycive Therapeutics, Inc. through an amended Schedule 13G filing.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Octagon Private Opportunities Fund II LP, and Ting Jia collectively reported beneficial ownership of 1,000,000 shares of Unicycive Therapeutics, Inc. Common Stock.
• This aggregate ownership represents 7.8% of the company's outstanding Common Stock.
• The percentage is calculated based on 12,768,239 Common Shares outstanding as of June 18, 2025, as reported in the Issuer's Form 8-K filed on June 20, 2025.
• Octagon Capital Advisors LP and Ting Jia each beneficially own 1,000,000 shares, representing 7.8% of the class.
• Octagon Investments Master Fund LP beneficially owns 650,000 shares, representing 5.1% of the class.
• Octagon Private Opportunities Fund II LP beneficially owns 350,000 shares, representing 2.7% of the class.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to previously reported ownership or status.
• The reporting persons explicitly state that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of beneficial ownership, indicating a significant passive investment. It does not contain positive or negative operational news for the company, thus a neutral sentiment.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, and its affiliates, along with Ting Jia, have taken a substantial 7.8% stake in Unicycive Therapeutics, Inc., signaling confidence in the company.
• The filing indicates a passive investment intent, which may reduce concerns about potential activist campaigns or disruptive changes to company control.

Negatives

• The filing does not indicate any activist intent or plans to influence the control of Unicycive Therapeutics, Inc., which might disappoint investors seeking strategic changes from large shareholders.

Risks

• The reporting persons explicitly state that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer, limiting potential for shareholder-driven strategic shifts.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor holding a 7.8% stake may provide a degree of confidence or stability, as it indicates a substantial long-term, passive investment.

Key Dates

Keywords

Unicycive Therapeutics, Octagon Capital Advisors, Ting Jia, Schedule 13G, Beneficial Ownership, Institutional Investment, Equity Stake, Passive Investment